Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

New York (AFP) – Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential ...

Pfizer profits dipped on lower sales of Paxlovid - Copyright AFP/File Patrick T. Fallon Pfizer profits dipped on lower sales of Paxlovid - Copyright AFP/File Patrick ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to a lower rate of COVID-19 infections in the U.S. and a drop in purchases by governments. To be sure ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

Pfizer recorded lower first-quarter revenue ... The decline was driven by lower revenue from Covid-19 drug Paxlovid, which was partially offset by growth from its Covid-19 vaccine Comirnaty ...